Join
Live feed
·
PRReleasevia Quantisnow
Teva Pharmaceutical Industries Limited logo

Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results

ByQuantisnow·Wall Street's wire, on your screen.
TEVA· Teva Pharmaceutical Industries Limited
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TEVA (Teva Pharmaceutical Industries Limited) and more on Quantisnow.